AB-001

AB-001
Legal status
Legal status	CA: Schedule II; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class B;
Identifiers
	IUPAC name 1-Pentyl-3-(adamant-1-oyl)indole;
CAS Number	1345973-49-0 ;
PubChem CID	57404070;
ChemSpider	26286891 ;
UNII	H657DIA015;
CompTox Dashboard (EPA)	DTXSID90158822 ;
Chemical and physical data
Formula	C24H31NO
Molar mass	349.518 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCn1cc(c2c1cccc2)C(=O)C34CC5CC(C3)CC(C5)C4;
	InChI InChI=1S/C24H31NO/c1-2-3-6-9-25-16-21(20-7-4-5-8-22(20)25)23(26)24-13-17-10-18(14-24)12-19(11-17)15-24/h4-5,7-8,16-19H,2-3,6,9-15H2,1H3 ; Key:SHWDYCMMUPPWQM-UHFFFAOYSA-N ;
	(what is this?) (verify)

AB-001 (1-pentyl-3-(1-adamantoyl)indole) is a designer drug that was found as an ingredient in synthetic cannabis smoking blends in Ireland in 2010 and Hungary and Germany in 2011.^[1]^[2]^[3] It is unclear who AB-001 was originally developed by, but it is structurally related to compounds such as AM-1248 and its corresponding 1-(tetrahydropyran-4-ylmethyl) analogue, which are known to be potent cannabinoid agonists with moderate to a high selectivity for CB₂ over CB₁.^[4]^[5] The first published synthesis and pharmacological evaluation of AB-001 revealed that it acts as a full agonist at CB1 (EC₅₀ = 35 nM) and CB2 receptors (EC₅₀ = 48 nM).^[6] However, AB-001 was found to possess only weak cannabimimetic effects in rats at doses up to 30 mg/kg, making it less potent than the carboxamide analogue APICA, which possesses potent cannabimimetic activity at doses of 3 mg/kg.^[6]

Quick facts Legal status, Identifiers ...

[1]

[2]

[3]

[4]

[5]

[6]

AB-001

See also

References

Wikiwand - on